Form 4: Revolution Medicines COO Receives Equity Grant

Revolution Medicines, Inc. Chief Operating Officer Margaret A. Horn was granted 21,100 shares of common stock and options to purchase 47,600 shares.

Summary

• Margaret A. Horn, Chief Operating Officer of Revolution Medicines, Inc. (RVMD), was granted equity awards.
• On March 1, 2026, Horn acquired 21,100 shares of common stock at a price of $0 per share.
• Following this transaction, Horn beneficially owns 162,153 shares of common stock, which includes 82,326 restricted stock units.
• Additionally, on March 1, 2026, Horn was granted options to purchase 47,600 shares of common stock.
• These options have an exercise price of $102.02 per share and expire on February 28, 2036.
• The options will vest monthly over four years, with 1/48th vesting on each monthly anniversary starting March 1, 2026, contingent on continued service.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices designed to align management's interests with long-term shareholder value. It signals continued commitment from a key executive.

Positives

• The Chief Operating Officer received a significant grant of 21,100 shares of common stock at no cost, increasing her direct equity stake in the company.
• The grant of 47,600 stock options provides a long-term incentive for the COO, aligning her interests with shareholder value creation, particularly given the exercise price of $102.02.
• The vesting schedule over four years encourages long-term commitment and retention of a key executive.

Risks

• The vesting of both the restricted stock units and the stock options is contingent upon the Reporting Person's continued service through each vesting date.
• The value of the stock options is dependent on the future market price of Revolution Medicines, Inc. common stock exceeding the exercise price of $102.02.

Future Outlook

The stock options granted to the Chief Operating Officer will vest over a four-year period, with 1/48th of the shares vesting monthly starting March 1, 2026, contingent on continued service. This aligns executive incentives with long-term company performance.

Industry Context

StockSavvy.ai notes that equity grants to key executives like the Chief Operating Officer are a standard practice in the biotechnology and pharmaceutical industry, particularly for growth-oriented companies like Revolution Medicines, Inc. These grants are designed to attract, retain, and motivate top talent by aligning their financial interests with the long-term success and share price appreciation of the company. The four-year vesting schedule is also typical for such long-term incentive plans.

Comparison to Industry Standards

• The four-year monthly vesting schedule for stock options is a common industry standard for executive long-term incentive plans, comparable to practices at companies like Moderna (MRNA) or BioNTech (BNTX) for their executive equity awards.
• Granting restricted stock units (RSUs) at a $0 price is standard for compensatory equity awards, similar to how many tech and biotech companies structure their RSU grants to executives.
• The exercise price of $102.02 for the options, while not explicitly compared to market price in the filing, is typically set at or above the fair market value on the grant date, a common practice to ensure options are performance-based.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Operating Officer's financial incentives with long-term shareholder value creation, potentially leading to more focused efforts on company growth and stock performance.
• Employees: Standard executive compensation practices, including equity grants, can signal stability and a commitment to retaining key leadership, which can positively influence employee morale.

Next Steps

• The stock options will begin vesting on March 1, 2026, with 1/48th of the shares vesting monthly.
• The options will be fully vested and exercisable as of March 1, 2030, assuming continued service.
• The options will expire on February 28, 2036.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive, which is a standard practice for executive compensation and retention. While positive for aligning management incentives, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals rather than this specific insider transaction.

Keywords

Revolution Medicines, RVMD, Form 4, Insider Transaction, Equity Grant, Stock Options, Restricted Stock Units, Executive Compensation, Margaret Horn, Chief Operating Officer